Tik Shing Cheung

Tik Shing Cheung

Auto-generated profile, based on publicly available information

Tik Shing Cheung

School of Cancer and Pharmacological Sciences and KHP Cancer Research UK Centre, King's College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
AGAntonio Galleu
Antonio Galleu
YVYanira Vasquez
Yanira Vasquez
CTCristina Trento
Cristina Trento
CLCara Lomas
Cara Lomas
LDLuigi Dolcetti
Luigi Dolcetti
FDFrancesco Dazzi
Francesco Dazzi
Mesenchymal stromal cell apoptosis, induced in vivo by recipient cytotoxic cells, is required for immunosuppression and clinical responses.

17 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KNKarol Nowicki-Osuch
Karol Nowicki-Osuch
LZLizhe Zhuang
Lizhe Zhuang
TCTik Shing Cheung
Tik Shing Cheung
EBEmily L. Black
Emily L. Black
NMNeus Masqué-Soler
Neus Masqué-Soler
RFRebecca C. Fitzgerald
Rebecca C. Fitzgerald
Intestinal metaplasia in the esophagus (Barrett's esophagus IM, or BE-IM) and stomach (GIM) are considered precursors for esophageal and gastric adenocarcinoma, respectively. We hypothesize that BE-IM and GIM follow parallel developmental trajectories in response to differing inflammatory insults. Here, we construct a single-cell RNA-sequencing atlas, supported by protein expression studies, of the entire gastrointestinal tract spanning physiologically normal and pathologic states including gastric metaplasia in the esophagus (E-GM), BE-IM, atrophic gastritis, and GIM. We demonstrate that BE-IM and GIM share molecular features, and individual cells simultaneously possess transcriptional properties of gastric and intestinal epithelia, suggesting phenotypic mosaicism. Transcriptionally E-GM resembles atrophic gastritis; genetically, it is clonal and has a lower mutational burden than BE-IM. Finally, we show that GIM and BE-IM acquire a protumorigenic, activated fibroblast microenvironment. These findings suggest that BE-IM and GIM can be considered molecularly similar entities in adjacent organs, opening the path for shared detection and treatment strategies. Significance: Our data capture the gradual molecular and phenotypic transition from a gastric to intestinal phenotype (IM) in the esophagus and stomach. Because BE-IM and GIM can predispose to cancer, this new understanding of a common developmental trajectory could pave the way for a more unified approach to detection and treatment. See related commentary by Stachler, p. 1291. This article is highlighted in the In This Issue feature, p. 1275

25 June 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TCTik Shing Cheung
Tik Shing Cheung
GBGiuliana Minani Bertolino
Giuliana Minani Bertolino
CGChiara Giacomini
Chiara Giacomini
MBMartin Bornhäuser
Martin Bornhäuser
FDFrancesco Dazzi
Francesco Dazzi
AGAntonio Galleu
Antonio Galleu
The immunosuppressive activity of mesenchymal stromal cells (MSCs) in graft versus host disease (GvHD) is well-documented, but their therapeutic benefit is rather unpredictable. Prospective randomized clinical trials remain the only means to address MSC clinical efficacy. However, the imperfect understanding of MSC biological mechanisms has undermined patients' stratification and the successful design of clinical studies. Furthermore, although MSC efficacy seems to be dependent on patient-associated factors, the role of patients' signature to predict and/or monitor clinical outcomes remains poorly elucidated. The analysis of GvHD patient serum has identified a set of molecules that are associated with high mortality. However, despite their importance in defining GvHD severity, their role in predicting or monitoring response to MSCs has not been confirmed. A new perspective on the use of MSCs for GvHD has been prompted by the recent findings that MSCs are actively induced to undergo apoptosis by recipient cytotoxic cells and that this process is essential to initiate MSC-induced immunosuppression. This discovery has not only reconciled the conundrum between MSC efficacy and their lack of engraftment, but also highlighted the determinant role of the patient in promoting and delivering MSC immunosuppression. In this review we will revisit the extensive use of MSCs for the treatment of GvHD and will elaborate on the need that future clinical trials must depend on mechanistic approaches that facilitate the development of robust and consistent assays to stratify patients and monitor clinical outcomes.

7 March 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
TCTik Shing Cheung
Tik Shing Cheung
AGAntonio Galleu
Antonio Galleu
MBMalte von Bonin
Malte von Bonin
MBMartin Bornhäuser
Martin Bornhäuser
FDFrancesco Dazzi
Francesco Dazzi

7 October 2023 in Molecular Therapy
Verified
Journal Article
Open access
TCTik Shing Cheung
Tik Shing Cheung
CGChiara Giacomini
Chiara Giacomini
MCMatteo Cereda
Matteo Cereda
AAAlvaro Avivar-Valderas
Alvaro Avivar-Valderas
DCDaria Capece
Daria Capece
FDFrancesco Dazzi
Francesco Dazzi
In vivo apoptosis of human mesenchymal stromal cells (MSCs) plays a critical role in delivering immunomodulation. Yet, caspase activity not only mediates the dying process but also death-independent functions that may shape the immunogenicity of apoptotic cells. Therefore, a better characterization of the immunological profile of apoptotic MSCs (ApoMSCs) could shed light on their mechanistic action and therapeutic applications. We analyzed the transcriptomes of MSCs undergoing apoptosis and identified several immunomodulatory factors and chemokines dependent on caspase activation following Fas stimulation. The ApoMSC secretome inhibited human T cell proliferation and activation, and chemoattracted monocytes in vitro. Both immunomodulatory activities were dependent on the cyclooxygenase2 (COX2)/prostaglandin E2 (PGE2) axis. To assess the clinical relevance of ApoMSC signature, we used the peripheral blood mononuclear cells (PBMCs) from a cohort of fistulizing Crohn's Disease (CD) patients who had undergone MSC treatment (ADMIRE-CD). Compared to healthy donors, MSCs exposed to patients' PBMCs underwent apoptosis and released PGE2 in a caspase-dependent manner. Both PGE2 and apoptosis were significantly associated with clinical responses to MSCs. Our findings identify a new mechanism whereby caspase activation delivers ApoMSC immunosuppression. Remarkably, such molecular signatures could implicate translational tools for predicting patients' clinical responses to MSC therapy in CD.

1 February 2018 in Seminars in Immunology
Verified
Journal Article
Closed access
TCTik Shing Cheung
Tik Shing Cheung
FDFrancesco Dazzi
Francesco Dazzi